Total bilirubin >4 mg/dL precluding ceftriaxone use or metronidazole intolerance
4-7 days after source control in localized IAI
Consider a 2-week course in patients with bloodstream infections
Please refer to PH Guidelines for Management of Gram-Negative Bloodstream Infections in Adults for further guidance
Daily assessment of antimicrobial regimen is strongly encouraged: 1) Revision of empirical antimicrobial therapy based on identification of microorganism 2) Further streamlining to definitive therapy based on antimicrobial susceptibility testing results
The non-stratified use of fluoroquinolones for empirical therapy of hospitalized adults with IAI is not recommended due to increasing rates of antimicrobial resistance among E. coli and other gram-negative isolates.